We are improving the lives of people suffering from mental illness and substance use disorders

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

JULY 14, 2022
Q2 Interim Report - Good tailwind in the financial development

JULY 13, 2022 
Deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule  

JULY 6, 2022
Invitation to presentation of the Q2 Interim Report on July 14 at 2 pm

 

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).

MODIA® - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

News Flow

Regulatory Press Releases

Orexo Social

19 July 2022

Soon a week ago. #orexo/#deprexis + Veterans Affairs #depression #digitalhealth pic.twitter.com/6ilWJaduJZ

18 July 2022

Dagens ⁦@SvDNaringsliv⁩ - en sammanfattning av Q2s finansiella utveckling. #orexo pic.twitter.com/Im2mIxOW4V

15 July 2022

Färsk intervju där hälsovårdsanalytikern Klas Palin på Erik Penser Bank för en dialog med #orexos VD Nikolaj Sorens… https://t.co/KRdU1tK3vT

Financial Snapshot

Group net revenues

597  MSEK

LTM1

Group EBITDA

-126 MSEK

LTM1

US Pharma segment EBIT

312 MSEK

LTM1

Cash position

468 MSEK

Q2 2022

1 Last Twelve Months, Q321-Q222, for more information about financial development Link